Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Daclatasvir

An antiviral for hepatitis C, the first inhibitor of the viral protein NS5A to reach the market: approved in 2014 in Japan and Europe and in 2015 in the United States, it is always used in combination with other antivirals. This family brings together the active ingredient, labelled standards and other impurities.

Did you know?It was found through phenotypic screening: instead of starting from a known target, researchers tested molecules on cultured human liver cells in which the virus RNA was replicating, the so-called replicon system.

DaclatasvirActive ingredientDaclatasvirCat. No. P-D004-002CAS 1009119-64-5
Daclatasvir-d6Isotopically labelledDaclatasvir-d6Cat. No. P-D004-005CAS 1801709-41-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.